Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

被引：0

作者：

Joana Barros-Martins

Swantje I. Hammerschmidt

Anne Cossmann

Ivan Odak

Metodi V. Stankov

Gema Morillas Ramos

Alexandra Dopfer-Jablonka

Annika Heidemann

Christiane Ritter

Michaela Friedrichsen

Christian Schultze-Florey

Inga Ravens

Stefanie Willenzon

Anja Bubke

Jasmin Ristenpart

Anika Janssen

George Ssebyatika

Günter Bernhardt

Jan Münch

Markus Hoffmann

Stefan Pöhlmann

Thomas Krey

Berislav Bošnjak

Reinhold Förster

Georg M. N. Behrens

机构：

[1] Hannover Medical School,Institute of Immunology

[2] Hannover Medical School,Department for Rheumatology and Immunology

[3] Partner Site Hannover-Braunschweig,German Center for Infection Research (DZIF)

[4] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem

[5] University of Lübeck,Cell Transplantation

[6] Ulm University Medical Center,Institute of Biochemistry

[7] Institute of Molecular Virology,German Center for Infection Research (DZIF)

[8] Infection Biology Unit,undefined

[9] German Primate Center,undefined

[10] Faculty of Biology and Psychology,undefined

[11] Georg-August-University Göttingen,undefined

[12] Partner Site Hannover-Braunschweig and Partner Site Hamburg-Lübeck-Borstel-Riems,undefined

[13] Cluster of Excellence RESIST (EXC 2155),undefined

[14] Hannover Medical School,undefined

[15] CiiM,undefined

[16] Centre for Individualised Infection Medicine,undefined

来源：

Nature Medicine | 2021年 / 27卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer’s BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.

引用

页码：1525 / 1529

页数：4

共 13 条

[1] Polack FP(2020)Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N. Engl. J. Med. 383 2603-2615
[2] Baden LR(2021)Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N. Engl. J. Med. 384 403-416
[3] Wise J(2021)Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots BMJ 372 n699-1868
[4] Pottegård A(2021)Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study BMJ 373 n1114-2211
[5] Abdool Karim SS(2021)New SARS-CoV-2 variants—clinical, public health, and vaccine implications N. Engl. J. Med. 384 1866-924
[6] de Oliveira T(2021)Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Cell 184 2201-1362
[7] Supasa P(2021)Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Nat. Med. 27 917-849
[8] Planas D(2021)Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Lancet 397 1351-634
[9] Emary KRW(2020)Strategic anti-SARS-CoV-2 serology testing in a low prevalence setting: the COVID-19 Contact (CoCo) Study in healthcare professionals Infect. Dis. Ther. 9 837-1468
[10] Behrens GMN(2020)Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals Infection 48 631-1153

← 1 2 →